Testing a drug to slow down aortic valve disease
Part of Heart & circulation clinical trials.
This trial tests if a medication called PCSK-9 inhibitor can slow the progression of calcified aortic valve disease, a condition where the heart's aortic valve becomes stiff and narrow. It is for people who also have heart disease or very high cholesterol that hasn't been controlled well with statins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with aortic stenosis (narrowing of the aortic valve) by an ultrasound of your heart.
- You also have either heart or blood vessel disease, or very high LDL ('bad') cholesterol (4.9 mmol/L or higher).
- Your cholesterol is still high even after taking the highest dose of statins you can tolerate.
- You are not already taking or allergic to PCSK-9 inhibitors.
- You are not pregnant, breastfeeding, or planning a valve replacement soon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding PCSK9 inhibitor injections (to statin treatment) can slow or improve calcific aortic valve stenosis, a condition where the heart’s aortic valve becomes stiff and narrowed. It’s aimed at adults with mild-to-moderate disease or certain people with severe disease but no symptoms.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This trial tests whether a PCSK9 inhibitor (a cholesterol-lowering medicine) can slow the progression of calcific aortic stenosis, a heart valve condition. It may be an option for people with mild or moderate valve narrowing who are not yet ready for surgery.
This trial tests a new pill, ataciguat, to slow down the progression of moderate calcific aortic valve stenosis (a condition where your aortic valve stiffens). If you have moderate valve narrowing and meet the other criteria, participation could help find a way to delay needing surgery.
This trial tests whether a powerful cholesterol-lowering drug (PCSK9 inhibitor) helps stabilize plaque in heart arteries after a recent heart attack or unstable angina treated with a stent. It may lower the risk of future heart problems.
This trial tests if the drug vericiguat can slow down the buildup of calcium in the aortic valve, which causes it to narrow and stiffen. If you have mild-to-moderate aortic valve stenosis and meet the other criteria, this study may help protect your valve from getting worse.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.